Two new hires at Fate Therapeutics get stock awards that vest over four years if they stay
Fate Therapeutics (FATE) granted equity inducement awards to two new non-executive employees on October 1, 2026. These awards include options to purchase 62,900 common shares at $2.30 per share for one employee and restricted stock units (RSUs) representing 72,700 common shares for two employees, including the option recipient. Both the stock options and RSUs will vest over a four-year period, contingent upon continued employment.
Fate Therapeutics, Inc. (FATE) stock price, news, quote and history
This article provides a detailed overview of Fate Therapeutics, Inc. (FATE), including its current stock price, recent performance, and key financial data. It highlights the company's focus on developing programmed cellular immunotherapies for cancer and immune disorders, along with its pipeline of CAR-targeted NK and T-cell product candidates. The report also includes analyst ratings, earnings trends, and valuation measures for FATE.
Fate Therapeutics, Inc. (F6T.F) Stock Price, News, Quote & History
This Yahoo Finance page provides a comprehensive overview of Fate Therapeutics, Inc. (F6T.F) stock, including its current price, historical performance, and key financial data. The company is a clinical-stage biopharmaceutical firm focused on developing cellular immunotherapies for cancer and immune disorders. The article details the company's product candidates and financial metrics such as market cap, EPS, and recent returns compared to the S&P 500.
Fate Therapeutics to Participate in Upcoming Fourth Quarter 2026 Conferences
Fate Therapeutics, Inc. announced its participation in two investor conferences in the fourth quarter of 2026: the Jefferies Global Healthcare Conference in November and the Piper Sandler 38th Annual Healthcare Conference in December. The company, a clinical-stage biopharmaceutical firm focusing on iPSC-derived cellular immunotherapies, may give a presentation or fireside chat at these events. Webcasts of these events will be available on their investor relations website.
Gross profit of Fate Therapeutics, Inc. – HAN:F6T
The article focuses on the gross profit of Fate Therapeutics, Inc., traded under the symbol F6T on the Hannover Stock Exchange. It indicates that the market for F6T was closed with no trades reported at the time of publication. The content primarily lists various features and offerings of the TradingView platform, where this financial information is hosted.
Fate Therapeutics receives $15m CIRM grant for lupus trial
Fate Therapeutics has been awarded a $15 million grant from the California Institute for Regenerative Medicine (CIRM) to fund its Phase 2 clinical trial for FT819, an off-the-shelf CAR T-cell therapy targeting lupus nephritis. The RECLAIM-LN trial will evaluate FT819 in patients with refractory moderate-to-severe Systemic Lupus Erythematosus with Lupus Nephritis, a serious condition affecting 150,000 U.S. patients and a leading cause of kidney failure. This funding supports the development of FT819, which has already shown favorable safety and tolerability in preliminary Phase 1 data.
Fate Therapeutics Receives $15 Million CIRM Grant to Advance Phase 2 RECLAIM-LN Trial of FT819 in Lupus Nephritis
Fate Therapeutics has secured a $15 million grant from the California Institute for Regenerative Medicine (CIRM) to further its Phase 2 RECLAIM-LN clinical trial. This trial will evaluate FT819, an off-the-shelf CAR T-cell therapy, for patients suffering from refractory moderate-to-severe Systemic Lupus Erythematosus (SLE) and lupus nephritis. The funding aims to accelerate the development of this potentially transformative therapy and enhance patient access, particularly as FT819 allows for outpatient treatment and targets a significant unmet medical need.
Fate Therapeutics receives $15m CIRM grant for lupus trial By Investing.com
Fate Therapeutics has been awarded a $15 million grant from the California Institute for Regenerative Medicine (CIRM) to support its Phase 2 clinical trial of FT819, a CAR T-cell therapy for lupus nephritis. This grant, part of CIRM's CLIN2 program, will fund the RECLAIM-LN trial, which evaluates FT819 in patients with refractory moderate-to-severe Systemic Lupus Erythematosus with Lupus Nephritis. Lupus nephritis is a serious condition affecting approximately 150,000 patients in the United States and is a leading cause of kidney failure among lupus patients.
Fate Therapeutics Announces Receipt of California Institute
Fate Therapeutics has received a $15.0 million grant from the California Institute for Regenerative Medicine (CIRM) through its CLIN2 program. This funding will support the clinical development of RECLAIM-LN, a Phase 2 trial of FT819, an off-the-shelf CAR T-cell therapy for patients with refractory moderate-to-severe Systemic Lupus Erythematosus (SLE) with Lupus Nephritis (LN). The CLIN2 grant is a highly competitive award aimed at advancing clinical trials for stem cell and gene therapies with the potential for transformative patient benefits.
Fate Therapeutics Announces Receipt of California Institute for Regenerative Medicine (CIRM) CLIN2 Grant to Advance RECLAIM-LN
Fate Therapeutics has received a $15.0 million CLIN2 grant from the California Institute for Regenerative Medicine (CIRM) to advance its Phase 2 RECLAIM-LN trial. This trial will evaluate FT819, an off-the-shelf CAR T-cell therapy, for patients with refractory moderate-to-severe Systemic Lupus Erythematosus with Lupus Nephritis. The grant underscores the potential of FT819 to provide a transformative and accessible treatment option for this serious autoimmune disease.
Fate Therapeutics Receives $15 Million Grant for Lupus Treatment Trial
Fate Therapeutics has been awarded a $15 million grant from the California Institute for Regenerative Medicine. This grant is intended to support a lupus treatment trial. The full details of the article are behind a premium paywall.
Fate Therapeutics Selected for Four Presentations Highlighting its Off-the-Shelf CAR T-Cell Portfolio in Autoimmune Disease at ACR Convergence 2026
Fate Therapeutics announced that four abstracts from its off-the-shelf CAR T-cell programs have been selected for presentation at ACR Convergence 2026. The presentations will cover clinical data for FT819, including administration without conditioning chemotherapy and outpatient administration, a patient perspective study on CAR T-cell therapy in lupus, and an update on FT839 for rheumatoid arthritis. The company emphasizes its commitment to making cell therapy accessible and improving the quality of life for patients with autoimmune diseases.
Fate Therapeutics Selected for Four Presentations Highlighting its Off-the-Shelf CAR T-Cell Portfolio in Autoimmune Disease at ACR Convergence 2026
Fate Therapeutics announced that four abstracts from its off-the-shelf CAR T-cell programs, including FT819 and FT839, have been selected for presentation at the American College of Rheumatology (ACR) Convergence 2026. The presentations will cover updated clinical data for FT819, a patient perspective study on CAR T-cell therapy in lupus, and updates on the preclinical studies and clinical trial design for FT839. This highlights the company's commitment to making accessible and transformative cell therapy for autoimmune diseases.
Fate Therapeutics, Inc. (NASDAQ:FATE) Given Average Rating of "Hold" by Analysts
Analysts have assigned an average "Hold" rating to Fate Therapeutics, Inc. (NASDAQ:FATE) based on reports from eight firms, with a 12-month average target price of $5.90 against its current price of $2.31. The company, which is a clinical-stage biopharmaceutical firm, recently met EPS expectations but continues to show significant losses. Institutional investors hold a substantial 97.54% of the company's stock.
Fate Therapeutics Announces Encore Clinical Data
Fate Therapeutics announced encore clinical data from its FT819 off-the-shelf anti-CD19 CAR T-cell product candidate in systemic lupus erythematosus (SLE), which will be presented at the CCR – West 2026 meeting. The data highlights favorable tolerability and early, maintained efficacy, supporting its RECLAIM-LN trial for lupus nephritis. Additionally, preclinical data for its FT839 dual-CAR T-cell therapy will also be presented.
Sixteen lupus patients had no severe immune reactions in early cell-therapy data
Fate Therapeutics (FATE) is set to present encore Phase 1 clinical data for its off-the-shelf anti-CD19 CAR T-cell candidate, FT819, in systemic lupus erythematosus (SLE) at the CCR – West meeting. The data covers 16 SLE patients who received FT819 with less-intensive conditioning, showing no dose-limiting toxicities or severe immune reactions. The positive safety and efficacy results, including improvements in disease activity and kidney outcome measures, are being used to support the company's potentially registrational Phase 2 RECLAIM-LN trial for lupus nephritis.
Fate Therapeutics Announces Encore Clinical Data Presentation of FT819 Off-the-Shelf CAR T-Cell Product Candidate at the CCR – West 2026 Meeting
Fate Therapeutics announced it will present encore clinical data for its off-the-shelf anti-CD19 CAR T-cell product candidate FT819 at the Congress of Clinical Rheumatology West (CCR – West) meeting in September 2026. The presentation will include safety, efficacy, and translational data from 16 systemic lupus erythematosus (SLE) patients treated in a Phase 1 trial, showing favorable tolerability and early, maintained efficacy. This data supports the ongoing RECLAIM-LN trial, a Phase 2 study for lupus nephritis.
Fate Therapeutics to Present FT819 and FT839 Data at CCR West Meeting, Highlighting Safety and Efficacy in Autoimmune Disease
Fate Therapeutics announced it will present clinical and preclinical data for its anti-CD19 CAR T-cell candidates, FT819 and FT839, at the Congress of Clinical Rheumatology West from September 17-20, 2026. The presentation will include Phase 1 trial findings for FT819, showing favorable safety and early efficacy in systemic lupus erythematosus (SLE) and lupus nephritis. Data highlights improved disease activity and patient-reported outcomes with minimal toxicities, supporting its potential as a treatment for autoimmune diseases.
Fate Therapeutics: RECLAIM-LN Underway, Additional Clinical Updates Ahead (NASDAQ:FATE)
Fate Therapeutics (NASDAQ: FATE) has initiated the phase 2 RECLAIM-LN trial for FT819 in lupus nephritis, with the first patient dosed in an outpatient setting and plans to open 20 sites by year-end 2026. Interim analysis data from multiple patients is expected in the second half of 2027. Earlier phase 1 data for FT819 in systemic lupus erythematosus, including lupus nephritis patients, showed reductions in disease activity, and the company is also progressing FT819 in systemic sclerosis and FT836 in colorectal cancer.
A lupus trial that could support approval is on Fate Therapeutics’ agenda Sept. 9.
Fate Therapeutics (FATE) will participate in a fireside chat at the 2026 Annual Cantor Global Healthcare Conference on September 9, 2026. The company will discuss FT819, its CAR T-cell candidate for autoimmune diseases, including the Phase 2 RECLAIM-LN lupus nephritis trial and FT819’s safety design. Management will also host one-on-one investor meetings, with a webcast replay available for 30 days.
Fate Therapeutics to Participate in Fireside Chat at the 2026 Annual Cantor Global Healthcare Conference
Fate Therapeutics, a clinical-stage biopharmaceutical company, announced its participation in a fireside chat at the 2026 Annual Cantor Global Healthcare Conference. Management will discuss their off-the-shelf CAR T-cell product candidate, FT819, for autoimmune diseases, including the initiation of the RECLAIM-LN Phase 2 trial for lupus nephritis, and will also host one-on-one investor meetings. A webcast of the event will be available on the company's website.
BlackRock Inc. Makes New Investment in Fate Therapeutics, Inc. $FATE
BlackRock Inc. recently acquired over 7.3 million shares of Fate Therapeutics, Inc. (NASDAQ:FATE) valued at approximately $19.7 million, giving it a 6.26% stake in the biopharmaceutical company. Other institutional investors also made new investments, with institutional ownership now at 97.54%. Fate Therapeutics reported an in-line quarterly loss of $0.25 per share but exceeded revenue forecasts, with analysts predicting a full-year loss of $1.06 per share.
Fate Therapeutics to Participate in Fireside Chat at the 2026 Annual Cantor Global Healthcare Conference
Fate Therapeutics, Inc. (NASDAQ: FATE) announced its participation in a fireside chat at the 2026 Annual Cantor Global Healthcare Conference on September 9, 2026. Management will discuss their off-the-shelf CAR T-cell product candidate, FT819, for autoimmune diseases, including the commencement of its Phase 2 RECLAIM-LN trial for lupus nephritis. They will also highlight the unique safety features of FT819 and host one-on-one meetings with investors.
574,995 Shares in Fate Therapeutics, Inc. $FATE Acquired by Connor Clark & Lunn Investment Management Ltd.
Connor Clark & Lunn Investment Management Ltd. has acquired 574,995 shares of Fate Therapeutics, Inc. (NASDAQ:FATE) during the second quarter, valued at approximately $1.55 million, giving them a 0.49% stake in the company. Institutional investors collectively own 97.54% of Fate Therapeutics. Analyst sentiment for FATE is mixed, with a consensus "Hold" rating and an average target price of $5.90, despite the stock trading down 4.3% recently.
Fate Therapeutics, Inc. (NASDAQ:FATE) Given Consensus Recommendation of "Hold" by Brokerages
Fate Therapeutics, Inc. (NASDAQ:FATE) has received a consensus "Hold" rating from eight brokerages, with an average 12-month price target of $5.90. The biopharmaceutical company, which focuses on iPSC-derived cellular immunotherapies, reported quarterly revenue of $2.08 million and an adjusted loss of $0.25 per share, matching analyst expectations. Institutional investors hold a significant 97.54% stake in the company, with recent activity from BlackRock and Johnson & Johnson.
Dimensional Fund Advisors LP Lowers Stock Holdings in Fate Therapeutics, Inc. $FATE
Dimensional Fund Advisors LP significantly reduced its stake in Fate Therapeutics, Inc. by 44.0% in the first quarter, selling 693,688 shares and retaining 883,790 shares valued at approximately $1.06 million. Despite this, institutional investors and hedge funds still collectively own 97.54% of the company. Fate Therapeutics reported an EPS of -$0.25, meeting analyst expectations, with revenue exceeding forecasts, though the company remains unprofitable and analysts project a full-year EPS loss of $1.04.
Fate Therapeutics (FATE) Stock Drifts Higher Despite Persistent Cash Burn
Fate Therapeutics (FATE) stock saw a modest increase despite reporting significant losses in Q2 2026, with a net loss of US$30 million. While the company's revenue slightly increased year-over-year and losses narrowed, funding risk remains due to its substantial cash burn. Bullish sentiment is supported by positive early clinical data for FT819, but skeptics point to the ongoing losses and recent stock price declines.
Fate Therapeutics Doses First Patient in Phase 2 RECLAIM-LN Trial of FT819 for Lupus Nephritis
Fate Therapeutics has dosed the first patient in its Phase 2 RECLAIM-LN trial for FT819, an off-the-shelf CAR T-cell therapy aimed at treating refractory moderate-to-severe systemic lupus erythematosus with lupus nephritis. The trial, which plans to enroll approximately 53 patients, will evaluate FT819's efficacy and safety, with complete renal response at Week 26 as the primary endpoint. This study benefits from FDA's RMAT designation and participation in the CMC Development and Readiness Pilot program, indicating a potential for an accelerated regulatory path.
Fate Therapeutics Initiates Potentially Registrational Trial of Off-the-Shelf CAR T-Cell Therapy FT819 for Lupus Nephritis
Fate Therapeutics has started RECLAIM-LN, a Phase 2 registrational trial for its off-the-shelf CAR T-cell therapy FT819, targeting refractory lupus nephritis. This follows positive Phase 1 safety and efficacy data. The trial, developed with FDA interaction, aims to enroll 53 patients, with preliminary data indicating significant improvements in disease activity and a favorable safety profile.
Wedbush Reaffirms "Outperform" Rating for Fate Therapeutics (NASDAQ:FATE)
Wedbush has reaffirmed an "Outperform" rating for Fate Therapeutics (NASDAQ:FATE), setting a target price of $7.00, which suggests a significant upside of approximately 178% from its current share price. The biopharmaceutical company recently surpassed quarterly expectations, reporting a smaller-than-anticipated loss of $0.25 per share and revenues of $2.08 million, exceeding the $1.37 million consensus. Despite an overall "Hold" rating from other analysts, the stock has a consensus price target of $5.38.
Fate Therapeutics doses first patient in FT819 lupus trial
Fate Therapeutics has dosed the first patient in its Phase 2 RECLAIM-LN clinical trial for FT819, a treatment for refractory moderate-to-severe systemic lupus erythematosus with lupus nephritis. The trial aims to enroll approximately 53 patients with Class III or IV lupus nephritis, expecting to complete enrollment by the first half of 2028. FT819, an off-the-shelf CAR T-cell product, has received Regenerative Medicine Advanced Therapy designation from the FDA, with preliminary Phase 1 data showing promising improvements in disease activity.
Fate Therapeutics' First FT819 Patient Went Home Same Day
Fate Therapeutics has initiated its RECLAIM-LN Phase 2 clinical trial for FT819, an off-the-shelf CAR T-cell therapy, in patients with lupus nephritis. The first patient was dosed in an outpatient setting and discharged the same day, with the study aiming to enroll approximately 53 patients by the first half of 2028. This trial leverages RMAT designation and FDA CMC pilot program participation for a potential accelerated regulatory pathway, building on favorable safety and efficacy observations from earlier studies.
Fate Therapeutics Initiates Potentially Registrational RECLAIM-LN Clinical Trial of FT819 for the Treatment of Lupus Nephritis
Fate Therapeutics has initiated its potentially registrational Phase 2 RECLAIM-LN clinical trial for FT819, an off-the-shelf CAR T-cell therapy, to treat refractory moderate-to-severe systemic lupus erythematosus (SLE) with lupus nephritis. The first patient has been dosed in an outpatient setting, and the study aims to enroll approximately 53 patients, with results expected by the first half of 2028. This trial leverages the FDA's RMAT designation and CMC Development and Readiness Pilot program, building on promising Phase 1 safety and efficacy data.
Fate Therapeutics earnings beat by $0.02, revenue topped estimates
Fate Therapeutics (NASDAQ: FATE) announced second-quarter EPS of $-0.250, surpassing analyst estimates by $0.02, and reported revenue of $2.08 million, exceeding the consensus of $1.29 million. The company's stock has seen significant growth, rising 43.590% in the last three months and 131.190% over the past year. InvestingPro rates Fate Therapeutics' financial health as "fair performance."
FATE THERAPEUTICS, INC. : WELLS FARGO RAISES TARGET PRICE TO $3.5 FROM $2.5
Wells Fargo has increased its target price for FATE Therapeutics, Inc. (FATE.O) to $3.5 from $2.5. This update was reported by Reuters on August 14, 2026. The article is a brief financial news alert.
Fate Therapeutics Initiates Potentially Registrational RECLAIM-LN Clinical Trial of FT819 for the Treatment of Lupus Nephritis
Fate Therapeutics has initiated the potentially registrational RECLAIM-LN Phase 2 clinical trial for FT819, an off-the-shelf CAR T-cell therapy, for patients with refractory moderate-to-severe lupus nephritis. The trial aims to enroll approximately 53 patients, with the first patient already dosed in an outpatient setting. FT819 has received RMAT designation and participates in the FDA's CDRP program, supporting an accelerated regulatory pathway.
Form 8K Fate Therapeutics Inc For: 13 August By Investing.com
This article announces the filing of a Form 8K by Fate Therapeutics Inc. for August 13. It includes the company's stock symbol FATE and notes a 1.98% increase. The content is a brief financial update presented by Investing.com.
Fate Therapeutics: Q2 Earnings Snapshot
This article provides a brief earnings snapshot for Fate Therapeutics (FATE) for the second quarter. It indicates that the company reported its Q2 results, though specific financial details are not included in the provided content. The article itself is very short and does not offer any further analysis or data.
Fate Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates
Fate Therapeutics announced its second quarter 2026 financial results, highlighting the initiation of its Phase 2 RECLAIM-LN trial for FT819 in lupus nephritis and the FDA clearance of the FT839 IND application for autoimmune disease. The company reported a cash runway extending into 2028 and presented preliminary clinical data for FT819 in systemic sclerosis and FT836 in colorectal cancer. Additionally, Laura Hamill was appointed to the Board of Directors, bringing commercial expertise as the company moves towards later-stage development.
Fate Therapeutics (NASDAQ:FATE) Posts Quarterly Earnings Results, Beats Expectations By $0.02 EPS
Fate Therapeutics (NASDAQ:FATE) reported its quarterly earnings, exceeding analyst expectations with an adjusted loss of $0.25 per share, $0.02 better than estimates, and revenue of $2.08 million against a consensus of $1.37 million. Despite beating expectations, the biopharmaceutical company remains unprofitable, showing a negative net margin of 2,056.79% and a negative return on equity of 58.89%. Analysts have a mixed sentiment, with an average "Hold" rating and a consensus price target of $6.00, while institutional investors hold a significant majority of the outstanding shares.
Fate Therapeutics reports Q2 2026: $2.1M revenue, $30.2M net loss, cash $153.8M
Fate Therapeutics announced its Q2 2026 financial results, reporting $2.1 million in revenue and a net loss of $30.2 million. The company ended the quarter with $153.8 million in cash and expects its cash runway to extend into 2028. Additionally, Fate Therapeutics highlighted significant clinical advancements in its iPSC-derived off-the-shelf CAR T programs, including progress in trials for lupus nephritis and other autoimmune indications.
Fate Therapeutics: Q2 Earnings Snapshot
Fate Therapeutics (FATE) reported a Q2 GAAP loss of $0.65 per share, which was narrower than the prior year's loss of $0.69 per share. While the company did not generate revenue in the quarter, the results indicate a slight improvement in its financial performance compared to the same period last year.
Form 8K Fate Therapeutics Inc For: 13 August By Investing.com
This article from Investing.com reports on the filing of a Form 8K by Fate Therapeutics Inc. for August 13. The brief notice indicates a regulatory filing has been made by the company. It includes no further details about the content of the Form 8K, simply confirming its existence.
Fate Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates
Fate Therapeutics announced its Q2 2026 financial results, highlighting significant clinical milestones including the dosing of the first lupus nephritis patient in its RECLAIM-LN trial for FT819 with same-day discharge. The company also reported FDA clearance for FT839's IND application for an autoimmune disease trial and preliminary positive data for FT819 in SLE and systemic sclerosis. Despite a sequential decrease in cash, Fate Therapeutics projects its cash runway will extend into 2028.
Fate Therapeutics Reports $30.2 Million Second-Quarter Net Loss
Fate Therapeutics (FATE) reported a second-quarter 2026 net loss of $30.2 million on $2.1 million in revenue. The company initiated a Phase 2 trial for lupus nephritis and received FDA clearance for another CAR T-cell product candidate, while its cash reserves declined by $21 million during the quarter. Insider trading shows sales by executives, and institutional investors have mixed positions.
Fate Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates
Fate Therapeutics announced its second-quarter 2026 financial results and provided business updates. Key highlights include the dosing of the first lupus nephritis patient in its RECLAIM-LN trial for FT819, FDA clearance for the FT839 IND application for autoimmune disease, and preliminary positive clinical data for FT819 in systemic sclerosis. The company also reported a cash runway extending into 2028 and the appointment of Laura Hamill to its Board of Directors.
Renaissance Technologies LLC Increases Holdings in Fate Therapeutics, Inc. $FATE
Renaissance Technologies LLC has increased its stake in Fate Therapeutics, Inc. (NASDAQ:FATE) by 26% during the first quarter, now owning 2.97 million shares valued at approximately $3.57 million. Other institutional investors have also adjusted their holdings, contributing to institutional ownership of 97.54% of the company. Despite mixed analyst sentiment and a "Hold" rating, the biopharmaceutical company reported a first-quarter loss of $0.26 per share, beating estimates, though revenue fell short of forecasts.
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Fate Therapeutics announced the granting of inducement awards to newly-hired non-executive employees under Nasdaq Listing Rule 5635(c)(4). These awards include non-qualified stock options for 37,300 shares and restricted stock units for 45,300 shares, intended to incentivize new hires. The awards vest over four years, contingent on continuous employment.
Don't Ignore The Insider Selling In Fate Therapeutics
Fate Therapeutics (NASDAQ: FATE) recently saw its President, Bahram Valamehr, sell US$108k worth of stock, representing a 23% reduction in his holdings. This sale, at a price slightly below the current market value, is the largest insider sale in the past year for the company. Coupled with a low insider ownership of 1.5%, this activity suggests caution regarding the stock, as there has been no insider buying in the last three months or the past year.
Fate Therapeutics Inc expected to post a loss of 27 cents a share - Earnings Preview
Fate Therapeutics Inc is anticipated to report a loss of 27 cents per share. This information comes from a Reuters earnings preview available on TradingView, which cites Refinitiv as the source for this financial projection.
